A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participants must have a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either non-squamous or squamous histology; mixed histology is allowed). 2) Participants must have advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) NSCLC. 3) Participants must have completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab.

You may not be eligible for this study if the following are true:

  • 1) Participants have mixed small cell lung cancer or sarcomatoid variant NSCLC. 2) Participants have received prior PARP inhibitor(s) in prior lines of treatment. 3) Participants have systolic BP >140 mmHg and/or diastolic BP >90 mmHg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.